ADmit Therapeutics SL
About
ADmit Therapeutics has developed the MAP-AD Test, the first prognostic blood test for Alzheimer's disease (AD) dementia. Using patented mitochondrial DNA biomarkers and AI, it predicts progression to AD in patients with first memory complaints, even before amyloid positivity. This facilitates early personalized interventions, optimizes clinical trial enrollment, and empowers patients and clinicians with crucial foresight. Our solution improves quality of life and offers significant economic savings.
Type of Cooperation
Clinical validation
Development Stage (TRL)
TRL 8
Sector
Diagnostics
Therapeutic Area
Diseases of the nervous system / neurology
Representatives
CEO
ADmit Therapeutics SL